We are honored and proud to receive the GHP Biotechnology Awards as the Best Antibody Conjugate Therapy Development Company in 2023. Thank you for the recognition as we continue to strive hard for the benefit of cancer patients worldwide.


About Axcynsis Therapeutics Pte. Ltd.
Axcynsis Therapeutics Pte. Ltd. is a platform-based biotechnology company focusing on the development of Antibody Drug Conjugates (ADCs) to revolutionise cancer treatments. The Singapore biotech start-up leverages on proprietary technologies in its development of a robust pipeline of ADC candidates to address unmet medical needs for cancer treatment.

For all media queries, please contact: